img click


Recent News

arrowMay 5, 2011
Escape SCILL Interns to Attend ISSCR 9th Annual Meeting in Toronto.

arrowNovember 2, 2010
Escape secures exclusive worldwide rights from Stanford University for a novel Botox formulation.

arrowNovember 2, 2010
Escape secures exclusive license with Stanford University for a novel bone growth protein.

About Escape Therapeutics

Since its founding in 2006, Escape Therapeutics has dedicated itself to transforming healthcare through discovery, development, and commercialization of innovative stem cell-based curative therapeutics capable of relieving the suffering of children and adults inflicted with devastating diseases or injuries that are currently inadequately treated and/or incurable.

Headquartered in Silicon Valley, California, the company has built an elite team of Stanford-trained scientists with core expertise in stem cell immunology and genetic engineering. This has fueled a series of significant scientific advances over the past 4 years, bringing Escape only months away from the creation of the world's first universal pluripotent stem cell source. Escape's primary areas of focus include type I diabetes, acute myocardial infarction, and acute and chronic skin wounds.

2010 Escape Therapeutics, Inc. All rights reserved.

Website design by Sylvia Do & Chris Nye